Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cellectar Biosciences, Inc.

Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Announces Plan to Explore Strategic Alternatives
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences to Present at the 37th Annual Roth Conference
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Tickers CLRB
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.